Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
9.80
+0.34 (3.59%)
At close: Oct 13, 2025, 4:00 PM EDT
9.80
0.00 (0.00%)
After-hours: Oct 13, 2025, 5:49 PM EDT
Arvinas Revenue
Arvinas had revenue of $22.40M in the quarter ending June 30, 2025, a decrease of -70.72%. This brings the company's revenue in the last twelve months to $372.80M, up 299.57% year-over-year. In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth.
Revenue (ttm)
$372.80M
Revenue Growth
+299.57%
P/S Ratio
1.90
Revenue / Employee
$866,977
Employees
430
Market Cap
719.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ARVN News
- 11 hours ago - Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress - GlobeNewsWire
- 8 days ago - Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire
- 12 days ago - Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire
- 26 days ago - Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party - Reuters
- 26 days ago - Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation - GlobeNewsWire
- 4 weeks ago - Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer - GlobeNewsWire